IGF2BP1 and hepatocellular carcinoma: For example, hsa-miR-150/IGF2BP1 regulatory pair was reported to be a novel potential therapeutic target for osteosarcoma treatment (65), and IGF2BP1 was identified as a novel target gene of hsa-miR-98-5p in hepatocellular carcinoma (66).